Novartis sues to protect bone meds; Pfizer price-fixing suit dismissed;

> Novartis filed a lawsuit in the United States against Israeli generic drugmaker Teva, over patents for its bone disease treatments Zometa and Reclast. Report

> A California appeals court upheld the dismissal of a 2004 lawsuit against Pfizer and 18 other drugmakers, which alleged they conspired to inflate prices to keep cheaper meds from Canada out of the U.S. Report

> Endo Pharmaceuticals and Penwest Pharmaceuticals have sued generic drug maker Impax for patent infringement related to the pain treatment oxymorphone hydrochloride, a.k.a. Opana ER. Report

> Ivax has sued GlaxoSmithKline for patent infringement in Ireland, over various asthma inhalers sold in that country. Report

> The European Commission Tuesday deepened its antitrust investigation in Pfizer's plan to buy several animal health product franchises from Schering-Plough. Report

> A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. Report

> Shares of Chugai, which is controlled by Roche, jumped on the news that FDA staffers had sounded a distinctly positive note about Actemra for rheumatoid arthritis. Actemra report

> Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy--MK-8122--on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and formulation options. Merck report

> Shares of Vanda Pharmaceuticals plunged after the FDA issued a non-approvable letter for its lead therapy, the schizophrenia drug iloperidone. Vanda report

> Amgen issued some eagerly awaited late-stage data on its bone drug denosumab which demonstrated a lower risk of spine and hip fractures among women with osteoporosis. Denosumab report

> Contract research organizations are playing a growing role helping small biotech companies develop early-stage therapeutics, according to a new report from Turner Investment Partners. CRO report

And Finally... Drugs for ED can help cancer treatments better penetrate the brain. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.